Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects with Rheumatoid Arthritis

Exclusion Criteria

• - Prior to Day 0, use of
• a. Abatacept
• b. Rituximab within 6 months
• c. Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or Mycophenolate mofetil within 2 months
• d. Etanercept or Anakinra within 28 days
• e. Immunoglobulin or blood products within 28 days
• - Evidence of any active or recent infection including ongoing, chronic infectious disease such as chronic renal infection or chronic chest infection with bronchiectasis or sinusitis
• - History of systemic autoimmune disease other than Rheumatoid Arthritis
• - History of allergic reactions to other protein therapeutics such as monoclonal antibodies or fusion proteins
• - History of anaphylaxis or allergic diathesis
• - Clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram
• - Evidence of active or latent tuberculosis
• - Vaccination wtih live attenuated viruses within the 2 weeks prior to Day 0
• - Evidence of infection with hepatitis B virus, hepatitis C virus, human immunodeficiency virus 1 or 2, or active infection with hepatitis A
• - Pregnant or breastfeeding women